RxDoctor Payments Data

Scott Asakevich, MD

Internal Medicine · Tulsa, OKNPI 1356309769

Payments from drug & device makers

$484in general payments, 2019–2025

Across 25 payments — averaging $19.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$183
  • Novo Nordisk$105
  • Dexcom, Inc.$55
  • Amgen$48
  • Boehringer Ingelheim$25
  • Sumitomo Pharma America, Inc.$24
  • plus $44 from 2 others

What the payments were for

  • Food & beverage$484100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$484 in reported general payments places this provider in the 55th percentile of 840 internal medicine providers in Oklahoma.

See all internal medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$125,420
Medicare patients
356
Services billed
2,153

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban141$205,450
OzempicSemaglutide72$145,406
Trelegy ElliptaFluticasone/Umeclidin/Vilanter105$88,258
FarxigaDapagliflozin Propanediol66$83,391
TrulicityDulaglutide42$61,308
JardianceEmpagliflozin44$50,430
RybelsusSemaglutide16$41,463
XareltoRivaroxaban32$34,421
MounjaroTirzepatide23$29,901
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog42$28,335
MyrbetriqMirabegron26$28,146
Rosuvastatin Calcium486$20,330
Atorvastatin Calcium536$15,539
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$12,555
Duloxetine Hcl277$12,480

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$183$209,737171 claims
Novo NordiskOzempic, Rybelsus$105$186,87088 claims
Boehringer IngelheimJardiance$25$50,43044 claims
Astellas Pharma US IncMyrbetriq$21$28,14626 claims
AbbVieLumigan$23$3,48713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 840 internal medicine providers in Oklahoma.

Other internal medicine in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →